Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	ryanodine-sensitive calcium-release channel activity	RYR1 RYR2	8.76e-05	4	77	2	GO:0005219
GeneOntologyMolecularFunction	calcium-induced calcium release activity	RYR1 RYR2	2.18e-04	6	77	2	GO:0048763
GeneOntologyMolecularFunction	collagen binding	ITGA11 ABI3BP MMP9 TNXB	2.72e-04	81	77	4	GO:0005518
GeneOntologyMolecularFunction	alpha-glucosidase activity	GANAB GANC	3.04e-04	7	77	2	GO:0090599
GeneOntologyMolecularFunction	cysteine-type endopeptidase activity	GPAA1 USP11 UCHL1 CAPNS1	3.42e-04	86	77	4	GO:0004197
GeneOntologyMolecularFunction	UDP-xylosyltransferase activity	XXYLT1 GXYLT1	7.89e-04	11	77	2	GO:0035252
GeneOntologyMolecularFunction	xylosyltransferase activity	XXYLT1 GXYLT1	7.89e-04	11	77	2	GO:0042285
GeneOntologyMolecularFunction	ADP binding	MYH10 PPP5C PRKAG2	8.42e-04	48	77	3	GO:0043531
GeneOntologyMolecularFunction	cysteine-type peptidase activity	GPAA1 USP11 UCHL1 CAPNS1 USPL1	8.80e-04	192	77	5	GO:0008234
GeneOntologyBiologicalProcess	isoprenoid metabolic process	RDH11 LRP1 LRP2 ALG8 ALDH1A1 RPE65	1.65e-05	144	77	6	GO:0006720
GeneOntologyBiologicalProcess	retinoid metabolic process	RDH11 LRP1 LRP2 ALDH1A1 RPE65	2.07e-05	89	77	5	GO:0001523
GeneOntologyBiologicalProcess	diterpenoid metabolic process	RDH11 LRP1 LRP2 ALDH1A1 RPE65	2.69e-05	94	77	5	GO:0016101
GeneOntologyBiologicalProcess	terpenoid metabolic process	RDH11 LRP1 LRP2 ALDH1A1 RPE65	4.59e-05	105	77	5	GO:0006721
GeneOntologyBiologicalProcess	positive regulation of lysosomal protein catabolic process	LRP1 LRP2	1.37e-04	5	77	2	GO:1905167
GeneOntologyBiologicalProcess	chemoattraction of axon	LRP1 LRP2	1.37e-04	5	77	2	GO:0061642
GeneOntologyBiologicalProcess	alcohol metabolic process	LMF1 RDH11 INPP5B LRP1 LRP2 ALG8 ALDH1A1 RPE65	1.50e-04	412	77	8	GO:0006066
GeneOntologyCellularComponent	endoplasmic reticulum membrane	ARHGAP32 LMF1 FATE1 GPAA1 RDH11 SAMD8 UCHL1 XXYLT1 PCYT2 ALG8 RPE65 PTGS2 RYR1 RYR2	3.16e-04	1293	79	14	GO:0005789
GeneOntologyCellularComponent	endoplasmic reticulum subcompartment	ARHGAP32 LMF1 FATE1 GPAA1 RDH11 SAMD8 UCHL1 XXYLT1 PCYT2 ALG8 RPE65 PTGS2 RYR1 RYR2	3.31e-04	1299	79	14	GO:0098827
GeneOntologyCellularComponent	nuclear outer membrane-endoplasmic reticulum membrane network	ARHGAP32 LMF1 FATE1 GPAA1 RDH11 SAMD8 UCHL1 XXYLT1 PCYT2 ALG8 RPE65 PTGS2 RYR1 RYR2	4.10e-04	1327	79	14	GO:0042175
GeneOntologyCellularComponent	junctional sarcoplasmic reticulum membrane	RYR1 RYR2	6.22e-04	10	79	2	GO:0014701
GeneOntologyCellularComponent	caspase complex	GPAA1 CAPNS1	6.22e-04	10	79	2	GO:0008303
GeneOntologyCellularComponent	dendrite	ARHGAP32 MYH10 PPP5C KCNB1 ABI3BP PLXDC1 FARP1 LRP1 LRP2 ARHGAP33	1.43e-03	858	79	10	GO:0030425
GeneOntologyCellularComponent	proximal dendrite	PPP5C KCNB1	1.43e-03	15	79	2	GO:1990635
GeneOntologyCellularComponent	protein complex involved in cell adhesion	ITGA11 ITGAE TNXB	1.45e-03	59	79	3	GO:0098636
GeneOntologyCellularComponent	dendritic tree	ARHGAP32 MYH10 PPP5C KCNB1 ABI3BP PLXDC1 FARP1 LRP1 LRP2 ARHGAP33	1.45e-03	860	79	10	GO:0097447
MousePheno	omphalocele	NDST1 MYH10 LRP1 LRP2 RYR1	4.16e-06	53	64	5	MP:0003052
MousePheno	decreased b-wave implicit time	CDH23 RPE65	2.06e-05	2	64	2	MP:0012149
MousePheno	abnormal abdominal wall morphology	NDST1 MYH10 LRP1 LRP2 RYR1	3.57e-05	82	64	5	MP:0003257
MousePheno	flat forehead	LHX2 LRP2	6.17e-05	3	64	2	MP:0030047
Domain	Glyco_hydro_31_N_dom	GANAB GANC	5.02e-05	3	77	2	IPR025887
Domain	Gal_mutarotas_2	GANAB GANC	5.02e-05	3	77	2	PF13802
Domain	Ryanrecept_TM4-6	RYR1 RYR2	5.02e-05	3	77	2	IPR009460
Domain	RyR	RYR1 RYR2	5.02e-05	3	77	2	PF02026
Domain	Ryanodine_rcpt	RYR1 RYR2	5.02e-05	3	77	2	IPR003032
Domain	RR_TM4-6	RYR1 RYR2	5.02e-05	3	77	2	PF06459
Domain	Ryan_recept	RYR1 RYR2	5.02e-05	3	77	2	IPR013333
Domain	RIH_assoc	RYR1 RYR2	2.49e-04	6	77	2	PF08454
Domain	RIH_assoc-dom	RYR1 RYR2	2.49e-04	6	77	2	IPR013662
Domain	RIH_dom	RYR1 RYR2	2.49e-04	6	77	2	IPR000699
Domain	Ins145_P3_rcpt	RYR1 RYR2	2.49e-04	6	77	2	IPR014821
Domain	Ryanodine_recept-rel	RYR1 RYR2	2.49e-04	6	77	2	IPR015925
Domain	PbH1	FBXO11 PKHD1L1	2.49e-04	6	77	2	SM00710
Domain	-	RYR1 RYR2	2.49e-04	6	77	2	1.25.10.30
Domain	Glyco_hydro_31_AS	GANAB GANC	2.49e-04	6	77	2	IPR030458
Domain	RYDR_ITPR	RYR1 RYR2	2.49e-04	6	77	2	PF01365
Domain	PbH1	FBXO11 PKHD1L1	2.49e-04	6	77	2	IPR006626
Domain	Ins145_P3_rec	RYR1 RYR2	2.49e-04	6	77	2	PF08709
Domain	Glyco_hydro_31	GANAB GANC	3.48e-04	7	77	2	IPR000322
Domain	Glyco_hydro_31	GANAB GANC	3.48e-04	7	77	2	PF01055
Domain	GLYCOSYL_HYDROL_F31_1	GANAB GANC	3.48e-04	7	77	2	PS00129
Domain	EF-hand_8	CAPNS1 RYR1 RYR2	3.68e-04	34	77	3	PF13833
Domain	PH-BEACH_dom	WDFY3 WDFY4	4.62e-04	8	77	2	IPR023362
Domain	-	WDFY3 WDFY4	4.62e-04	8	77	2	2.30.29.40
Domain	PH_BEACH	WDFY3 WDFY4	4.62e-04	8	77	2	PS51783
Domain	Pectin_lyase_fold/virulence	FBXO11 PKHD1L1	4.62e-04	8	77	2	IPR011050
Domain	-	LRP1 LRP2 TRIM71	5.53e-04	39	77	3	2.120.10.30
Domain	BEACH_dom	WDFY3 WDFY4	5.93e-04	9	77	2	IPR000409
Domain	BEACH	WDFY3 WDFY4	5.93e-04	9	77	2	PS50197
Domain	Beach	WDFY3 WDFY4	5.93e-04	9	77	2	PF02138
Domain	-	WDFY3 WDFY4	5.93e-04	9	77	2	1.10.1540.10
Domain	Beach	WDFY3 WDFY4	5.93e-04	9	77	2	SM01026
Domain	MIR	RYR1 RYR2	7.39e-04	10	77	2	PS50919
Domain	MIR	RYR1 RYR2	7.39e-04	10	77	2	PF02815
Domain	MIR	RYR1 RYR2	7.39e-04	10	77	2	SM00472
Domain	MIR_motif	RYR1 RYR2	7.39e-04	10	77	2	IPR016093
Domain	Glyco_transf_8	XXYLT1 GXYLT1	7.39e-04	10	77	2	PF01501
Domain	Glyco_trans_8	XXYLT1 GXYLT1	7.39e-04	10	77	2	IPR002495
Domain	6-blade_b-propeller_TolB-like	LRP1 LRP2 TRIM71	9.00e-04	46	77	3	IPR011042
Domain	PX	ARHGAP32 NISCH ARHGAP33	1.15e-03	50	77	3	PS50195
Domain	-	ARHGAP32 NISCH ARHGAP33	1.22e-03	51	77	3	3.30.1520.10
Domain	Phox	ARHGAP32 NISCH ARHGAP33	1.29e-03	52	77	3	IPR001683
Domain	Ldl_recept_b	LRP1 LRP2	1.48e-03	14	77	2	PF00058
Domain	LDLRB	LRP1 LRP2	1.48e-03	14	77	2	PS51120
Domain	LY	LRP1 LRP2	1.70e-03	15	77	2	SM00135
Domain	LDLR_classB_rpt	LRP1 LRP2	1.70e-03	15	77	2	IPR000033
Domain	EGF	LRP1 LRP2 TNXB PTGS2	1.83e-03	126	77	4	PF00008
Domain	RhoGAP	ARHGAP32 INPP5B ARHGAP33	2.14e-03	62	77	3	SM00324
Domain	Gal_mutarotase_SF_dom	GANAB GANC	2.19e-03	17	77	2	IPR011013
Domain	RhoGAP	ARHGAP32 INPP5B ARHGAP33	2.24e-03	63	77	3	PF00620
Domain	RHOGAP	ARHGAP32 INPP5B ARHGAP33	2.34e-03	64	77	3	PS50238
Domain	RhoGAP_dom	ARHGAP32 INPP5B ARHGAP33	2.34e-03	64	77	3	IPR000198
Domain	-	ARHGAP32 INPP5B ARHGAP33	2.34e-03	64	77	3	1.10.555.10
Domain	Integrin_alpha-2	ITGA11 ITGAE	2.46e-03	18	77	2	IPR013649
Domain	Integrin_alpha2	ITGA11 ITGAE	2.46e-03	18	77	2	PF08441
Domain	Integrin_alpha	ITGA11 ITGAE	2.46e-03	18	77	2	IPR000413
Domain	INTEGRIN_ALPHA	ITGA11 ITGAE	2.46e-03	18	77	2	PS00242
Domain	Int_alpha_beta-p	ITGA11 ITGAE	2.74e-03	19	77	2	IPR013519
Domain	Int_alpha	ITGA11 ITGAE	2.74e-03	19	77	2	SM00191
Domain	FG_GAP	ITGA11 ITGAE	3.67e-03	22	77	2	PS51470
Pubmed	Cyclooxygenase-2 deficiency enhances Th2 immune responses and impairs neutrophil recruitment in hepatic ischemia/reperfusion injury.	MMP9 PTGS2	5.23e-06	2	80	2	18209082
Pubmed	Skeletal and cardiac ryanodine receptors exhibit different responses to Ca2+ overload and luminal ca2+.	RYR1 RYR2	5.23e-06	2	80	2	17259277
Pubmed	Ryanodine receptor oligomeric interaction: identification of a putative binding region.	RYR1 RYR2	5.23e-06	2	80	2	14722100
Pubmed	Structural and functional interactions within ryanodine receptor.	RYR1 RYR2	5.23e-06	2	80	2	26009179
Pubmed	Structure and Function of the Human Ryanodine Receptors and Their Association with Myopathies-Present State, Challenges, and Perspectives.	RYR1 RYR2	5.23e-06	2	80	2	32899693
Pubmed	Differential expression of Low density lipoprotein Receptor-related Protein 1 (LRP-1) and matrix metalloproteinase-9 (MMP-9) in prostate gland: From normal to malignant lesions.	LRP1 MMP9	5.23e-06	2	80	2	27931798
Pubmed	Contribution of reactive oxygen species to migration/invasion of human glioblastoma cells U87 via ERK-dependent COX-2/PGE(2) activation.	MMP9 PTGS2	5.23e-06	2	80	2	19804834
Pubmed	Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability.	MMP9 PTGS2	5.23e-06	2	80	2	19946014
Pubmed	Ryanodine receptors in human pancreatic beta cells: localization and effects on insulin secretion.	RYR1 RYR2	5.23e-06	2	80	2	15033925
Pubmed	Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator.	LRP1 MMP9	5.23e-06	2	80	2	12960961
Pubmed	[Expression of COX-2 and MMP-9 in cervical carcinoma and their clinical significance].	MMP9 PTGS2	5.23e-06	2	80	2	18069634
Pubmed	Endocytic Protein Defects in the Neural Crest Cell Lineage and Its Pathway Are Associated with Congenital Heart Defects.	LRP1 LRP2	5.23e-06	2	80	2	34445520
Pubmed	Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1.	PLK1 PTGS2	5.23e-06	2	80	2	17265445
Pubmed	Cell type-specific spatial and functional coupling between mammalian brain Kv2.1 K+ channels and ryanodine receptors.	KCNB1 RYR1	5.23e-06	2	80	2	24962901
Pubmed	Aromatic-turmerone attenuates invasion and expression of MMP-9 and COX-2 through inhibition of NF-κB activation in TPA-induced breast cancer cells.	MMP9 PTGS2	5.23e-06	2	80	2	22740037
Pubmed	Recent advances in understanding the ryanodine receptor calcium release channels and their role in calcium signalling.	RYR1 RYR2	5.23e-06	2	80	2	30542613
Pubmed	Ryanodine receptors are expressed and functionally active in mouse spermatogenic cells and their inhibition interferes with spermatogonial differentiation.	RYR1 RYR2	5.23e-06	2	80	2	15280431
Pubmed	Expression of the ryanodine receptor isoforms in immune cells.	RYR1 RYR2	5.23e-06	2	80	2	11673493
Pubmed	B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators.	RYR1 RYR2	5.23e-06	2	80	2	11673462
Pubmed	Sensitized genetic backgrounds reveal differential roles for EGF repeat xylosyltransferases in Drosophila Notch signaling.	XXYLT1 GXYLT1	5.23e-06	2	80	2	30169771
Pubmed	Crystal structures of wild type and disease mutant forms of the ryanodine receptor SPRY2 domain.	RYR1 RYR2	5.23e-06	2	80	2	25370123
Pubmed	Inverse relationship between raft LRP1 localization and non-raft ERK1,2/MMP9 activation in idiopathic dilated cardiomyopathy: potential impact in ventricular remodeling.	LRP1 MMP9	5.23e-06	2	80	2	25131918
Pubmed	Cyclooxygenase-2 and matrix metalloproteinase-9 expressions correlate with tissue inflammation degree in periodontal disease.	MMP9 PTGS2	5.23e-06	2	80	2	26743292
Pubmed	Thermodynamics of calmodulin binding to cardiac and skeletal muscle ryanodine receptor ion channels.	RYR1 RYR2	5.23e-06	2	80	2	18618700
Pubmed	Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha.	MMP9 PTGS2	5.23e-06	2	80	2	19218340
Pubmed	Type 1 and type 3 ryanodine receptors are selectively involved in muscarinic antinociception in mice: an antisense study.	RYR1 RYR2	1.57e-05	3	80	2	18403125
Pubmed	Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice.	NDST1 LRP1	1.57e-05	3	80	2	23846497
Pubmed	[Effect of As(2)O(3) on expressions of COX-2 and matrix metalloproteinases in SGC7901 and K562 cells].	MMP9 PTGS2	1.57e-05	3	80	2	19236750
Pubmed	Clearance of matrix metalloproteinase-9 is dependent on low-density lipoprotein receptor-related protein-1 expression downregulated by microRNA-205 in human abdominal aortic aneurysm.	LRP1 MMP9	1.57e-05	3	80	2	26781079
Pubmed	Androgen receptor promotes the migration and invasion of upper urinary tract urothelial carcinoma cells through the upregulation of MMP-9 and COX-2.	MMP9 PTGS2	1.57e-05	3	80	2	23715826
Pubmed	The ryanodine receptor/calcium channel genes are widely and differentially expressed in murine brain and peripheral tissues.	RYR1 RYR2	1.57e-05	3	80	2	7876312
Pubmed	Dendritic differentiation of cerebellar Purkinje cells is promoted by ryanodine receptors expressed by Purkinje and granule cells.	RYR1 RYR2	1.57e-05	3	80	2	24123915
Pubmed	Increased cyclooxygenase activity impairs apoptosis of inflammatory neutrophils in mice lacking gelatinase B/matrix metalloproteinase-9.	MMP9 PTGS2	1.57e-05	3	80	2	19175797
Pubmed	Characterization of the tetratricopeptide-containing domain of BUB1, BUBR1, and PP5 proves that domain amphiphilicity over amino acid sequence specificity governs protein adsorption and interfacial activity.	PPP5C BUB1	1.57e-05	3	80	2	18547097
Pubmed	The low density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism.	LRP1 MMP9	1.57e-05	3	80	2	11279011
Pubmed	Expression of cyclooxygenase-2, matrix metalloproteinase-2 and matrix metalloproteinase-9 in premenopausal and postmenopausal endometrial polyps.	MMP9 PTGS2	1.57e-05	3	80	2	18378414
Pubmed	A prognostic classifier for patients with colorectal cancer liver metastasis, based on AURKA, PTGS2 and MMP9.	MMP9 PTGS2	1.57e-05	3	80	2	26497206
Pubmed	Matrix Metalloproteinases (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) expressions in vocal fold polyps.	MMP9 PTGS2	1.57e-05	3	80	2	17624726
Pubmed	Dopamine D1 receptor signaling system regulates ryanodine receptor expression in ethanol physical dependence.	RYR1 RYR2	1.57e-05	3	80	2	23278119
Pubmed	Molecular markers of therapeutic resistance in breast cancer.	ALDH1A1 PTGS2	1.57e-05	3	80	2	23434145
Pubmed	Microglial low-density lipoprotein receptor-related protein 1 mediates the effect of tissue-type plasminogen activator on matrix metalloproteinase-9 activity in the ischemic brain.	LRP1 MMP9	1.57e-05	3	80	2	19672275
Pubmed	Bidirectional coupling between ryanodine receptors and Ca2+ release-activated Ca2+ (CRAC) channel machinery sustains store-operated Ca2+ entry in human T lymphocytes.	RYR1 RYR2	1.57e-05	3	80	2	22948152
Pubmed	Developmental changes in expression of the three ryanodine receptor mRNAs in the mouse brain.	RYR1 RYR2	1.57e-05	3	80	2	10788707
Pubmed	Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.	MMP9 PTGS2	1.57e-05	3	80	2	22228328
Pubmed	Ca(2+)-induced Ca2+ release in myocytes from dyspedic mice lacking the type-1 ryanodine receptor.	RYR1 RYR2	1.57e-05	3	80	2	7621815
Pubmed	Relationship among LRP1 expression, Pyk2 phosphorylation and MMP-9 activation in left ventricular remodelling after myocardial infarction.	LRP1 MMP9	1.57e-05	3	80	2	28378397
Pubmed	Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9.	LRP1 MMP9	1.57e-05	3	80	2	19176371
Pubmed	Carbon monoxide ameliorates Staphylococcus aureus-elicited COX-2/IL-6/MMP-9-dependent human aortic endothelial cell migration and inflammatory responses.	MMP9 PTGS2	1.57e-05	3	80	2	30236480
Pubmed	Molecular identification of the ryanodine receptor pore-forming segment.	RYR1 RYR2	1.57e-05	3	80	2	10473538
Pubmed	MMP1, MMP9, and COX2 expressions in promonocytes are induced by breast cancer cells and correlate with collagen degradation, transformation-like morphological changes in MCF-10A acini, and tumor aggressiveness.	MMP9 PTGS2	1.57e-05	3	80	2	23762835
Pubmed	Changes and clinical significance of serum MMP-9, TIMP-1, COX-2, and immune levels in patients with asthma.	MMP9 PTGS2	1.57e-05	3	80	2	37937500
Pubmed	Hepatitis C virus NS3 protein enhances cancer cell invasion by activating matrix metalloproteinase-9 and cyclooxygenase-2 through ERK/p38/NF-κB signal cascade.	MMP9 PTGS2	1.57e-05	3	80	2	25305454
Pubmed	Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma.	MMP9 PTGS2	1.57e-05	3	80	2	17624083
Pubmed	Changes of nuclear factor kappa B (NF-kappaB), cyclooxygenase-2 (COX-2) and matrix metalloproteinase-9 (MMP-9) in human myometrium before and during term labor.	MMP9 PTGS2	1.57e-05	3	80	2	17011110
Pubmed	Heterogeneous gene expression and functional activity of ryanodine receptors in resistance and conduit pulmonary as well as mesenteric artery smooth muscle cells.	RYR1 RYR2	1.57e-05	3	80	2	18434746
Pubmed	SPRY domains in ryanodine receptors (Ca(2+)-release channels).	RYR1 RYR2	1.57e-05	3	80	2	9204703
Pubmed	Adhesive defect in extracellular matrix tenascin-X-null fibroblasts: a possible mechanism of tumor invasion.	MMP9 TNXB	1.57e-05	3	80	2	12419962
Pubmed	Ryanodine receptors are expressed in epidermal keratinocytes and associated with keratinocyte differentiation and epidermal permeability barrier homeostasis.	RYR1 RYR2	1.57e-05	3	80	2	21881589
Pubmed	Gonadotropins promote human ovarian cancer cell migration and invasion via a cyclooxygenase 2-dependent pathway.	MMP9 PTGS2	1.57e-05	3	80	2	28677781
Pubmed	Activated α(2) macroglobulin induces matrix metalloproteinase 9 expression by low-density lipoprotein receptor-related protein 1 through MAPK-ERK1/2 and NF-κB activation in macrophage-derived cell lines.	LRP1 MMP9	1.57e-05	3	80	2	20568116
Pubmed	Isoform-dependent formation of heteromeric Ca2+ release channels (ryanodine receptors).	RYR1 RYR2	1.57e-05	3	80	2	12213830
Pubmed	Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression.	LRP1 MMP9	1.57e-05	3	80	2	16303771
Pubmed	Expression of the ryanodine receptor type 3 calcium release channel during development and differentiation of mammalian skeletal muscle cells.	RYR1 RYR2	1.57e-05	3	80	2	9242641
Pubmed	Direct association of the reticulon protein RTN1A with the ryanodine receptor 2 in neurons.	RYR1 RYR2	1.57e-05	3	80	2	23454728
Pubmed	nc886, a non-coding RNA, inhibits UVB-induced MMP-9 and COX-2 expression via the PKR pathway in human keratinocytes.	MMP9 PTGS2	1.57e-05	3	80	2	30685091
Pubmed	Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations.	MMP9 PTGS2	1.57e-05	3	80	2	24670538
Pubmed	Calcineurin upregulates local Ca(2+) signaling through ryanodine receptor-1 in airway smooth muscle cells.	RYR1 RYR2	1.57e-05	3	80	2	25239916
Pubmed	Hypoxia induces metalloproteinase-9 activation and human vascular smooth muscle cell migration through low-density lipoprotein receptor-related protein 1-mediated Pyk2 phosphorylation.	LRP1 MMP9	1.57e-05	3	80	2	24072693
Pubmed	A gene-specific cerebral types 1, 2, and 3 RyR protein knockdown induces an antidepressant-like effect in mice.	RYR1 RYR2	1.57e-05	3	80	2	18643873
Pubmed	Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2).	RYR1 RYR2	1.57e-05	3	80	2	11159936
Pubmed	Intracellular calcium release channel expression during embryogenesis.	RYR1 RYR2	1.57e-05	3	80	2	9986730
Pubmed	Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages.	MMP9 PTGS2	1.57e-05	3	80	2	16338931
Pubmed	Chromosomal localization of murine ryanodine receptor genes RYR1, RYR2, and RYR3 by in situ hybridization.	RYR1 RYR2	1.57e-05	3	80	2	7959768
Pubmed	The organization of proteins in the human red blood cell membrane. A review.	RYR1 RYR2	1.57e-05	3	80	2	4600883
Pubmed	Regulation of mouse egg activation: presence of ryanodine receptors and effects of microinjected ryanodine and cyclic ADP ribose on uninseminated and inseminated eggs.	RYR1 RYR2	1.57e-05	3	80	2	7635066
Pubmed	Effect of N-(3-phenyl-2-propenyl)-1-deoxynojirimycin on the lectin binding to HIV-1 glycoproteins.	GANAB GANC GXYLT1	2.60e-05	25	80	3	2283726
Pubmed	Site-specific N-glycosylation and oligosaccharide structures of recombinant HIV-1 gp120 derived from a baculovirus expression system.	GANAB GANC GXYLT1	2.93e-05	26	80	3	8218172
Pubmed	Disabled-2 is essential for endodermal cell positioning and structure formation during mouse embryogenesis.	LRP1 LRP2	3.13e-05	4	80	2	12413896
Pubmed	Calmodulin modulates the termination threshold for cardiac ryanodine receptor-mediated Ca2+ release.	RYR1 RYR2	3.13e-05	4	80	2	23992453
Pubmed	Ryanodine receptor calcium release channels: lessons from structure-function studies.	RYR1 RYR2	3.13e-05	4	80	2	23413940
Pubmed	Effects of the imino sugar N-butyldeoxynojirimycin on the N-glycosylation of recombinant gp120.	GANAB GANC	3.13e-05	4	80	2	8416962
Pubmed	Association of matrix metalloproteinase (MMP-1, MMP-3 and MMP-9) and cyclooxygenase-2 gene polymorphisms and their proteins with chronic periodontitis.	MMP9 PTGS2	3.13e-05	4	80	2	21481333
Pubmed	Identification of the low density lipoprotein receptor-related protein (LRP) as an endocytic receptor for thrombospondin-1.	LRP1 LRP2	3.13e-05	4	80	2	7775583
Pubmed	Partial cloning and differential expression of ryanodine receptor/calcium-release channel genes in human tissues including the hippocampus and cerebellum.	RYR1 RYR2	3.13e-05	4	80	2	9607712
Pubmed	Differential requirements for the CENP-O complex reveal parallel PLK1 kinetochore recruitment pathways.	BUB1 PLK1	3.13e-05	4	80	2	33596090
Pubmed	Role of the Rho GTPase-activating protein RICS in neurite outgrowth.	ARHGAP32 PPP6R1	3.13e-05	4	80	2	16716191
Pubmed	Orostachys japonicus inhibits the expression of MMP-2 and MMP-9 mRNA and modulates the expression of iNOS and COX-2 genes in human PMA-differentiated THP-1 cells via inhibition of NF-κB and MAPK activation.	MMP9 PTGS2	3.13e-05	4	80	2	25760396
Pubmed	Hypoxia differently modulates gene expression of inositol 1,4,5-trisphosphate receptors in mouse kidney and HEK 293 cell line.	RYR1 RYR2	3.13e-05	4	80	2	19120137
Pubmed	FKBP binding characteristics of cardiac microsomes from diverse vertebrates.	RYR1 RYR2	3.13e-05	4	80	2	11237759
Pubmed	BUB1 and CENP-U, Primed by CDK1, Are the Main PLK1 Kinetochore Receptors in Mitosis.	BUB1 PLK1	3.13e-05	4	80	2	33248027
Pubmed	Conserved and divergent functions of Nfix in skeletal muscle development during vertebrate evolution.	RYR1 RYR2	3.13e-05	4	80	2	23482488
Pubmed	A glutathione deficit alters dopamine modulation of L-type calcium channels via D2 and ryanodine receptors in neurons.	RYR1 RYR2	3.13e-05	4	80	2	18206662
Pubmed	Increase of ryanodine receptors by dopamine D1 receptors is negatively regulated by γ-aminobutyric acid type B receptors in primary cultures of mouse cerebral cortical neurons.	RYR1 RYR2	3.13e-05	4	80	2	22504960
Pubmed	Retinol dehydrogenases RDH11 and RDH12 in the mouse retina: expression levels during development and regulation by oxidative stress.	RDH11 RPE65	3.13e-05	4	80	2	18326732
Pubmed	Isolated polycystic liver disease genes define effectors of polycystin-1 function.	GANAB ALG8	3.13e-05	4	80	2	28375157
Pubmed	Requirement for the ryanodine receptor type 3 for efficient contraction in neonatal skeletal muscles.	RYR1 RYR2	3.13e-05	4	80	2	9384575
Pubmed	Shugoshin 1 plays a central role in kinetochore assembly and is required for kinetochore targeting of Plk1.	BUB1 PLK1	3.13e-05	4	80	2	17617734
Pubmed	Role of apolipoprotein E receptors in regulating the differential in vivo neurotrophic effects of apolipoprotein E.	LRP1 LRP2	3.13e-05	4	80	2	11421580
Pubmed	S100A1 Protein Does Not Compete with Calmodulin for Ryanodine Receptor Binding but Structurally Alters the Ryanodine Receptor·Calmodulin Complex.	RYR1 RYR2	3.13e-05	4	80	2	27226555
Pubmed	LDL receptor-related protein 1 regulates the abundance of diverse cell-signaling proteins in the plasma membrane proteome.	PLXDC1 LRP1	3.13e-05	4	80	2	20919742
GeneFamily	Ryanodine receptors\|Protein phosphatase 1 regulatory subunits	RYR1 RYR2	2.15e-05	3	49	2	287
GeneFamily	Glycosyltransferase family 8	XXYLT1 GXYLT1	2.56e-04	9	49	2	436
GeneFamily	WD repeat domain containing\|BEACH domain containing	WDFY3 WDFY4	2.56e-04	9	49	2	1230
GeneFamily	Low density lipoprotein receptors	LRP1 LRP2	5.51e-04	13	49	2	634
GeneFamily	CD molecules\|Integrin alpha subunits	ITGA11 ITGAE	1.07e-03	18	49	2	1160
Coexpression	EIF4E_DN	ARHGAP32 MYH10 DENND2D WDFY3 MMP9 PTGS2	6.34e-07	100	80	6	M2790
ToppCell	facs-Mammary_Gland-Mammary_Gland-21m-Mesenchymal\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ITGA11 ABI3BP UCHL1 LRP1 CHRDL1 TNXB PTGS2	2.15e-08	169	79	7	bb43abad2c049b7f4d307737347290e01b3339a3
ToppCell	facs-Mammary_Gland-Mammary_Gland-21m-Mesenchymal-stromal_cell\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ITGA11 ABI3BP UCHL1 LRP1 CHRDL1 TNXB PTGS2	2.15e-08	169	79	7	5f18e3f40a5b1b167903f37516ec8181e889c7c5
ToppCell	facs-Mammary_Gland-Mammary_Gland-21m-Mesenchymal-stromal_cell\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ITGA11 ABI3BP UCHL1 LRP1 CHRDL1 TNXB PTGS2	2.15e-08	169	79	7	8bfa2d3bb541d02f55d7c95b8fd156c8403befca
ToppCell	ILEUM-inflamed-(7)_Endothelial_cell-(7)_Lymphatics\|(7)_Endothelial_cell / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	MYH10 ABI3BP CHRDL1 ALDH1A1 PRKAG2 PKHD1L1 TNXB	5.16e-08	192	79	7	d43caf42ec744e895137f31ef65a990e250669d2
ToppCell	5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MYH10 ABI3BP AOC3 LRP1 CHRDL1 TNXB RYR2	5.74e-08	195	79	7	df409f94f4e83be89f7a608058ee07ce3ce3a149
ToppCell	5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MYH10 ABI3BP AOC3 LRP1 CHRDL1 TNXB RYR2	5.74e-08	195	79	7	4243190ad291d56694e2155954dbaa879c9d3844
ToppCell	(5)_Fibroblasts-(5)_Fibroblast-E\|(5)_Fibroblasts / Lung cell shreds - cell class (v4) and cell subclass (v4)	CPXM2 ABI3BP PLXDC1 LRP1 CHRDL1 TNXB C16orf89	6.16e-08	197	79	7	9b1c1d72c5a8c90d71ae31e4c198d2276872eaa0
ToppCell	(5)_Fibroblast-G\|World / Lung cell shreds - cell class (v4) and cell subclass (v4)	MYH10 ABI3BP AOC3 LRP1 CHRDL1 ALDH1A1 TNXB	6.60e-08	199	79	7	b4a737575be9f8c65771832dd8cd25328d5dae0d
ToppCell	Transplant_Alveoli_and_parenchyma-Mesenchymal-Fibroblasts\|Mesenchymal / Tissue, Lineage and Cell class of Lung Cells from 10X	CPXM2 ABI3BP UCHL1 LRP1 ALDH1A1 TNXB C16orf89	6.60e-08	199	79	7	f19c683f38bca3bfee40396f27423441051dec67
ToppCell	343B-Fibroblasts-Fibroblast-G\|343B / Donor, Lineage, Cell class and subclass (all cells)	MYH10 ABI3BP AOC3 LRP1 CHRDL1 TNXB RYR2	6.60e-08	199	79	7	f4b6c095cbe7a38b310adc49be4069e4d56e6a66
ToppCell	343B-Fibroblasts-Fibroblast-G-\|343B / Donor, Lineage, Cell class and subclass (all cells)	MYH10 ABI3BP AOC3 LRP1 CHRDL1 TNXB RYR2	6.60e-08	199	79	7	9c6d1c328bfbb6547f4c7bb2a784576a56bd72af
ToppCell	343B-Fibroblasts\|343B / Donor, Lineage, Cell class and subclass (all cells)	MYH10 ABI3BP UCHL1 AOC3 LRP1 CHRDL1 TNXB	6.83e-08	200	79	7	376c1a77031e090be96948b47c78ac0d393f5775
ToppCell	5'-Adult-SmallIntestine-Mesenchymal-fibroblastic-Transitional_Stromal_3_(C3+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ITGA11 ABI3BP UCHL1 LRP1 CHRDL1 TNXB C16orf89	6.83e-08	200	79	7	6f7f015b5fa1f52374f2c7d9ba339012395eda5f
ToppCell	367C-Fibroblasts-Fibroblast-D-\|367C / Donor, Lineage, Cell class and subclass (all cells)	ABI3BP CCDC87 LRP1 CHRDL1 TNXB C16orf89	3.30e-07	154	79	6	dd3d34f065820e706515a13619f19a5b12734c8e
ToppCell	367C-Fibroblasts-Fibroblast-D\|367C / Donor, Lineage, Cell class and subclass (all cells)	ABI3BP CCDC87 LRP1 CHRDL1 TNXB C16orf89	3.30e-07	154	79	6	4bfda1c41efbb86d829b3797d1168bf2587c3c97
ToppCell	5'-Parenchyma_lung-Endothelial-Blood_vessel_EC-vein_endothelial_cell-EC_venous_pulmonary-EC_venous_pulmonary_L.2.2.1.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	TYMS CPXM2 ABI3BP BUB1 PLK1 TNXB	8.23e-07	180	79	6	40d4838a0ccb10d5e49266bc8a0037d27b75ccc2
ToppCell	5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MYH10 ABI3BP AOC3 CHRDL1 TNXB RYR2	9.96e-07	186	79	6	5473283fb95cee556b1f6934cf72169b676b5bcc
ToppCell	Healthy-multiplets\|Healthy / disease group, cell group and cell class	TYMS UCHL1 BUB1 PLK1 WDFY4 PKHD1L1	9.96e-07	186	79	6	2ec999b97e95afb898f8083042b0f188d3d234bc
ToppCell	5'-GW_trimst-2-LargeIntestine-Mesenchymal-myocytic-SMC_(PLPP2+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	KCNB1 CPXM2 AOC3 CHRDL1 ALDH1A1 RPE65	1.03e-06	187	79	6	3912bbb610a4a84791e9bda92a2d57a52c31d29e
ToppCell	droplet-Limb_Muscle-nan-21m-Mesenchymal\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ITGA11 CPXM2 ABI3BP LRP1 TNXB PTGS2	1.06e-06	188	79	6	2cfa41c64eccb28b5e22f0f91bbc921b75713245
ToppCell	droplet-Limb_Muscle-nan-21m-Mesenchymal-mesenchymal_stem_cell\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ITGA11 CPXM2 ABI3BP LRP1 TNXB PTGS2	1.09e-06	189	79	6	56f43e00d81cf3cdf0c39f8d7120f5beab72e258
ToppCell	facs-Diaphragm-Limb_Muscle-24m-Mesenchymal-mesenchymal_stem_cell\|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ITGA11 CPXM2 ABI3BP LRP1 TNXB PTGS2	1.13e-06	190	79	6	d13fd234caa3fc69d8a59bc0060cdacdf716ee55
ToppCell	ILEUM-non-inflamed-(7)_Endothelial_cell-(7)_Lymphatics\|(7)_Endothelial_cell / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	MYH10 ABI3BP CHRDL1 ALDH1A1 PKHD1L1 TNXB	1.13e-06	190	79	6	9ce301841ce9486701fa28eb2a9929e35d476878
ToppCell	3'-GW_trimst-1.5-SmallIntestine-Mesenchymal-myocytic\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	KCNB1 CPXM2 ABI3BP AOC3 CHRDL1 RPE65	1.24e-06	193	79	6	b1893193766ae41bf2ab6ed4083285c9c814e608
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	MYH10 ABI3BP CDH23 CHRDL1 TNXB RYR2	1.27e-06	194	79	6	e93de9428c986b8943fc169258847c650cfab0e5
ToppCell	IPF-Stromal-Fibroblast\|Stromal / Disease state, Lineage and Cell class	CPXM2 ABI3BP LRP1 CHRDL1 TNXB C16orf89	1.27e-06	194	79	6	da3e1d39575969a069ef43e552afe94b2f441d0b
ToppCell	3'-Broncho-tracheal-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-Adventitial_fibroblasts_L.2.1.0.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ITGA11 CPXM2 ABI3BP UCHL1 CHRDL1 TNXB	1.27e-06	194	79	6	35b30bc954750e939f81a9a7498b8bc2ce69a299
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MYH10 ABI3BP AOC3 CHRDL1 TNXB RYR2	1.35e-06	196	79	6	9737a5f006d37b549f281e1863aca558e1e4dc99
ToppCell	5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MYH10 ABI3BP AOC3 LRP1 CHRDL1 TNXB	1.35e-06	196	79	6	42e9828222a9663525d571633e8a454c30bfa7f8
ToppCell	facs-Marrow-KLS-3m-Myeloid-granulocyte_monocyte_progenitor_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TYMS THOP1 GPAA1 ALG8 MCCC1 PLK1	1.35e-06	196	79	6	c5adc95df9e1d1884a7988336e459a98c5a6769b
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MYH10 ABI3BP AOC3 CHRDL1 TNXB RYR2	1.35e-06	196	79	6	cecf82cd5e0a3835d655f5e7478578674a63ce25
ToppCell	5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.4.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MYH10 ABI3BP AOC3 CHRDL1 TNXB C16orf89	1.35e-06	196	79	6	988a3e0688e0a7ba69774497d3b130631bb26c50
ToppCell	facs-Marrow-KLS-3m-Myeloid-granulocyte_monocyte_progenitor_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TYMS THOP1 GPAA1 ALG8 MCCC1 PLK1	1.35e-06	196	79	6	81d1fd63397b2cf893607d828b61a926fa65185f
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	LHX2 MYH10 ABI3BP LRP1 TNXB RYR2	1.39e-06	197	79	6	fdb92985f7df0c280b87d3e43c2394e70786a2c7
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MYH10 ABI3BP AOC3 CHRDL1 TNXB RYR2	1.39e-06	197	79	6	94a9603cbd3516fbcce871909693b88f20d41713
ToppCell	10x_3'_v2v3-Neoplastic-Stem-like-NPC-like-NPC-like_Prolif-B\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	TYMS MYH10 FARP1 UCHL1 BUB1 PLK1	1.39e-06	197	79	6	196eaecef7003ed83f323c1f157c6a3594650097
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MYH10 ABI3BP AOC3 CHRDL1 TNXB RYR2	1.39e-06	197	79	6	13896ec65ccda0b928c91d41112dc01b480036b7
ToppCell	LPS_only-Endothelial-Endothelial-FOXM1\|LPS_only / Treatment groups by lineage, cell group, cell type	TYMS TPRA1 FATE1 BUB1 PLK1 RYR1	1.39e-06	197	79	6	038fd92750257d43d5e980fd06d77742b543f11a
ToppCell	COVID-19-lung-Fibroblast\|COVID-19 / Disease (COVID-19 only), tissue and cell type	MYH10 ABI3BP LRP1 CDH23 CHRDL1 RYR2	1.43e-06	198	79	6	3ec01a55ade5e1627258cc3cfebb2c3207a4cb43
ToppCell	tumor_Lung-Fibroblasts-COL13A1+_matrix_FBs\|tumor_Lung / Location, Cell class and cell subclass	MYH10 ABI3BP AOC3 LRP1 CHRDL1 TNXB	1.43e-06	198	79	6	2d7842f352273b6b823c86eb548b9f4a4cddf0ae
ToppCell	cellseq-Mesenchymal-Fibroblastic-Fibroblastic_2-AF1\|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	MYH10 ABI3BP AOC3 CHRDL1 TNXB RYR2	1.43e-06	198	79	6	f1374f7a50244d59c766ac41f44c08c9117407d2
ToppCell	367C-Fibroblasts-Fibroblast-E-\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	CPXM2 ABI3BP LRP1 CHRDL1 TNXB C16orf89	1.48e-06	199	79	6	2aed8f4a225a3762a5e7ce99aacad9b2a37d61f1
ToppCell	367C-Fibroblasts-Fibroblast-E\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	CPXM2 ABI3BP LRP1 CHRDL1 TNXB C16orf89	1.48e-06	199	79	6	c40ca26345753a2197bd9389d7323f7491c1e11d
ToppCell	cellseq-Mesenchymal-Fibroblastic-Fibroblastic_2\|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	MYH10 ABI3BP AOC3 CHRDL1 TNXB RYR2	1.48e-06	199	79	6	66a79732caf2f04c09b4d9832377aa01ca477677
ToppCell	LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	MYH10 ABI3BP LRP1 ALDH1A1 TNXB RYR2	1.48e-06	199	79	6	8b86c69aaf60feff53aa782559cfece7342a23de
ToppCell	5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-Adventitial_fibroblasts_L.2.1.0.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ITGA11 CPXM2 ABI3BP UCHL1 CHRDL1 TNXB	1.52e-06	200	79	6	3e6730c9ed7003a4acf501f699a4965a7a50f946
ToppCell	(5)_Fibroblasts\|World / Lung cell shreds - cell class (v4) and cell subclass (v4)	MYH10 ABI3BP UCHL1 LRP1 CHRDL1 TNXB	1.52e-06	200	79	6	22c839f27d3abdf86bfabdfa305f205dd899a9dc
ToppCell	Parenchymal-10x5prime-Stromal-Fibroblastic-Fibro_alveolar\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	MYH10 ABI3BP AOC3 CHRDL1 TNXB RYR2	1.52e-06	200	79	6	8c62f05c6042f24287a73fbdf80ff4a56f7ff403
ToppCell	367C-Fibroblasts-Fibroblast-E-\|367C / Donor, Lineage, Cell class and subclass (all cells)	ABI3BP UCHL1 LRP1 CHRDL1 TNXB C16orf89	1.52e-06	200	79	6	57b9d6aa2265ab178a5886f36ecc66115bd382a8
ToppCell	Parenchymal-10x3prime_v2-Stromal-Fibroblastic-Fibro_adventitial\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	CPXM2 ABI3BP UCHL1 LRP1 CHRDL1 TNXB	1.52e-06	200	79	6	fc3c4778841c4b8bac0afb458352614b2c460617
ToppCell	Parenchyma_Control_(B.)-Stromal-TX-Fibroblasts-1\|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type	MYH10 ABI3BP AOC3 CHRDL1 TNXB RYR2	1.52e-06	200	79	6	aa1a35dcca3b799241eef4237f6eb94660e019f0
ToppCell	Control_saline-Mesenchymal_myocytic-Myofibroblastic\|Control_saline / Treatment groups by lineage, cell group, cell type	MYH10 ABI3BP LRP1 CHRDL1 TNXB RYR2	1.52e-06	200	79	6	9d5b3c2dcfa55d50acc2ce2c319d51aa525d4cd1
ToppCell	Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Fibroblasts-1\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	MYH10 ABI3BP AOC3 CHRDL1 TNXB RYR2	1.52e-06	200	79	6	a510deaada669e690329183e18df02870bd204b3
ToppCell	Parenchymal-10x3prime_v2-Stromal\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	MYH10 AOC3 LRP1 CHRDL1 ALDH1A1 TNXB	1.52e-06	200	79	6	f6be0f24e607abb9007823a54fb0b24d04990a89
ToppCell	5'-Adult-SmallIntestine-Mesenchymal-fibroblastic\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ITGA11 ABI3BP LRP1 CHRDL1 TNXB C16orf89	1.52e-06	200	79	6	3a164e3971bcd62b148b813171c103adb81f972e
ToppCell	LPS_only-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_only / Treatment groups by lineage, cell group, cell type	MYH10 ABI3BP LRP1 ALDH1A1 TNXB RYR2	1.52e-06	200	79	6	a7ef7022b8efcaedb7319b0b43d8c4e99d788fe2
ToppCell	tumor_Lung-Fibroblasts\|tumor_Lung / Location, Cell class and cell subclass	MYH10 ABI3BP AOC3 LRP1 CHRDL1 TNXB	1.52e-06	200	79	6	073a68b5ce232203ffee86342cba2a00d907e119
ToppCell	Parenchymal-10x3prime_v2-Stromal-Fibroblastic\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	MYH10 ABI3BP LRP1 CHRDL1 ALDH1A1 TNXB	1.52e-06	200	79	6	fd92d8250c6ad1e8bb46b303ac37f8dcf80387d8
ToppCell	367C-Fibroblasts-Fibroblast-E\|367C / Donor, Lineage, Cell class and subclass (all cells)	ABI3BP UCHL1 LRP1 CHRDL1 TNXB C16orf89	1.52e-06	200	79	6	ddfbc004e7bd2fd3f11f046ed8fc049277160547
ToppCell	Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Fibroblasts-1-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	MYH10 ABI3BP AOC3 CHRDL1 TNXB RYR2	1.52e-06	200	79	6	dd4228cbed8a4395166a6332e08d44d88bebe3b9
ToppCell	droplet-Marrow-nan-21m-Lymphocytic-immature_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DENND2D ALDH1A1 MMP9 PKHD1L1 PTGS2	2.29e-06	119	79	5	aa3860c8d25c85baa79a0b6637bce2e269adfcc2
ToppCell	LPS_only-Endothelial-Endothelial-FOXM1\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TYMS PASK BUB1 PLK1 RPE65	4.11e-06	134	79	5	4d8f7ddad02fe76a614771e115ebb8e04623ba85
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-Mes-like\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	LRP1 PCYT2 TRIM71 DENND2D PLK1	1.07e-05	163	79	5	360cd65decda24853124f33a174f5224d7f3ce23
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-Mes-like-AT1_Progenitor\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	LRP1 PCYT2 TRIM71 DENND2D PLK1	1.07e-05	163	79	5	b59d9b4f7c9f4e5e2c7783a49a96729dae3a81e5
ToppCell	tumor_Lymph_Node_/_Brain-Fibroblasts-COL13A1+_matrix_FBs\|Fibroblasts / Location, Cell class and cell subclass	ABI3BP ALDH1A1 MCCC1 TNXB C16orf89	1.27e-05	169	79	5	84b898a9fd8ced67c6a501d5cef6416f519902c4
ToppCell	TCGA-Endometrium-Solid_Tissue_Normal-Endometrium_normal_tissue-Endometrium\|TCGA-Endometrium / Sample_Type by Project: Shred V9	KCNB1 ABI3BP AOC3 CHRDL1 TNXB	1.31e-05	170	79	5	cdc19013da7c41d1ed8400a6a643e4c684ff9912
ToppCell	TCGA-Endometrium-Solid_Tissue_Normal\|TCGA-Endometrium / Sample_Type by Project: Shred V9	KCNB1 ABI3BP AOC3 CHRDL1 TNXB	1.31e-05	170	79	5	0bde0a40440c7fdf7ba89cac8831d4014e7a4807
ToppCell	TCGA-Endometrium-Solid_Tissue_Normal-Endometrium_normal_tissue\|TCGA-Endometrium / Sample_Type by Project: Shred V9	KCNB1 ABI3BP AOC3 CHRDL1 TNXB	1.31e-05	170	79	5	516b38c4ecf6b0b04c5d4f80c510dcc00b328c6f
ToppCell	3'-Broncho-tracheal-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ITGA11 ABI3BP LRP1 CHRDL1 TNXB	1.38e-05	172	79	5	e37c0b5b547a7345179ab258dd2141fec7064c17
ToppCell	facs-Trachea-18m-Mesenchymal-fibroblast-fibroblast_of_trachea-tracheal_fibroblast_l20-1\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	PLXDC1 UCHL1 NISCH LRP1 TNXB	1.46e-05	174	79	5	1d157f7a919c8246e83d8060d2a0017c6c781ef3
ToppCell	systemic_lupus_erythematosus-managed-Lymphocytic_B-plasmablast-male\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	TYMS UCHL1 BUB1 PLK1 PKHD1L1	1.50e-05	175	79	5	89bf89466191da14896ed8928027f5b911436c22
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-Adaptive_/_Maladaptive_/_Repairing_Fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ABI3BP LRP1 CDH23 CHRDL1 TNXB	1.50e-05	175	79	5	795a6564d5a75ffd35d39f5274b9e8d28708bbc8
ToppCell	Influenza_Severe-Plasmablast\|World / Disease group and Cell class	TYMS UCHL1 BUB1 PLK1 PKHD1L1	1.50e-05	175	79	5	14df8fc6f6beae1be7b7bd5837546d1ac1239a6f
ToppCell	droplet-Lung-3m-Hematologic-myeloid-myeloid_dendritic_cell-proliferating_dendritic\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	BUB1 XXYLT1 ITGAE PLK1 WDFY4	1.54e-05	176	79	5	581045e61cdcdfa85701343d1a7c0a72a36606a7
ToppCell	Endothelial-B-SSc-ILD_02\|World / lung cells shred on cell class, cell subclass, sample id	CPXM2 PCDHB7 CHRDL1 PKHD1L1 TNXB	1.54e-05	176	79	5	b288116a4588a1f9db9d49af92cea118937c9201
ToppCell	343B-Fibroblasts-Fibroblast-A_(Fibroblast_progenitors)-\|343B / Donor, Lineage, Cell class and subclass (all cells)	ABI3BP UCHL1 LRP1 CHRDL1 TNXB	1.54e-05	176	79	5	2e94bbe17c0bb65dc58b4ebc0cb829258bd7373b
ToppCell	343B-Fibroblasts-Fibroblast-A_(Fibroblast_progenitors)\|343B / Donor, Lineage, Cell class and subclass (all cells)	ABI3BP UCHL1 LRP1 CHRDL1 TNXB	1.54e-05	176	79	5	f33ab41d121b59d871ad7d48ca021524a027d2ef
ToppCell	356C-Fibroblasts-Fibroblast-C_(Myofibroblast)-\|356C / Donor, Lineage, Cell class and subclass (all cells)	ITGA11 ABI3BP UCHL1 PCDHB7 RYR2	1.59e-05	177	79	5	cdfd2f0ee2f692271b1525e414b0f645cdadb1f6
ToppCell	systemic_lupus_erythematosus-treated-Lymphocytic_B-plasmablast-female\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	TYMS UCHL1 BUB1 PLK1 PKHD1L1	1.59e-05	177	79	5	d2c1f46913ac00bbc0bb9320d5652edc01b34179
ToppCell	356C-Fibroblasts-Fibroblast-C_(Myofibroblast)\|356C / Donor, Lineage, Cell class and subclass (all cells)	ITGA11 ABI3BP UCHL1 PCDHB7 RYR2	1.59e-05	177	79	5	db222faaecbe5600da39277243c4e7e764eb63c9
ToppCell	systemic_lupus_erythematosus-treated-Lymphocytic_B-plasmablast\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	TYMS UCHL1 BUB1 PLK1 PKHD1L1	1.59e-05	177	79	5	65e090aad0ffb737ce034e25bd5b12a0b1dd9684
ToppCell	Control-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ABI3BP LRP1 ALDH1A1 TNXB RYR2	1.72e-05	180	79	5	08ae0f5d95c45feba68ad99788f7af7ff4c979af
ToppCell	LPS-IL1RA-Endothelial-Endothelial-FOXM1\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TYMS BUB1 PLK1 RPE65 ARHGAP33	1.72e-05	180	79	5	334e2b1f6eb7d4ece20b1c7b02107863f913237f
ToppCell	3'-Broncho-tracheal-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-Adventitial_fibroblasts_L.2.1.2.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ITGA11 ABI3BP LRP1 CHRDL1 TNXB	1.81e-05	182	79	5	d179b5deb07c20d49eb6c58d5a65904f8921de3a
ToppCell	5'-Parenchyma_lung-Endothelial-Lymphatic_EC-endothelial_cell_of_lymphatic_vessel-Lymphatic_EC_differentiating-Lymphatic_EC_differentiating_L.2.5.1.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MYH10 ABI3BP CHRDL1 PKHD1L1 TNXB	1.86e-05	183	79	5	4d16bfbadf2cd13008c35e23dd2b5b4ecf92ee11
ToppCell	Control-Stromal_mesenchymal-Lung_smooth_muscle-MatrixFB_->_Myofibroblast\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ABI3BP LRP1 CHRDL1 TNXB RYR2	1.86e-05	183	79	5	7eae9b3b4d1c9b135fa7cff348393d4adec474b4
ToppCell	3'-Broncho-tracheal-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-Adventitial_fibroblasts_L.2.1.0.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ITGA11 CPXM2 ABI3BP CHRDL1 TNXB	1.91e-05	184	79	5	4a9f798c67b9998bffe44242b210cc1e224ff5b1
ToppCell	droplet-Limb_Muscle-Pre-Sort-18m-Mesenchymal\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CPXM2 LRP1 CHRDL1 TNXB RYR2	1.91e-05	184	79	5	c9d7ec17cc5b7ba1b1e721ca392746e8f4a3d41f
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-MatrixFB_->_Myofibroblast\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MYH10 ABI3BP LRP1 CHRDL1 TNXB	1.96e-05	185	79	5	3b2dfc8f4c87be516265dbecfc251276034d0efd
ToppCell	facs-Limb_Muscle-ForelimbandHindlimb-24m-Mesenchymal-mesenchymal_stem_cell\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ITGA11 ABI3BP LRP1 TNXB PTGS2	2.01e-05	186	79	5	ff6ccfdf2509f96caa10281c29a95b432f6c6dcc
ToppCell	5'-Parenchyma_lung-Endothelial-Lymphatic_EC-endothelial_cell_of_lymphatic_vessel-Lymphatic_EC_differentiating\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MYH10 ABI3BP CHRDL1 PKHD1L1 TNXB	2.01e-05	186	79	5	40070d9cd20188ba49b32acfca9bc16256b38bf5
ToppCell	droplet-Spleen-SPLEEN-30m-Hematologic\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TYMS MYH10 BUB1 ALDH1A1 PLK1	2.01e-05	186	79	5	ac6e32cf07f0f013101ca7aedae0c562857f182b
ToppCell	mild_COVID-19-Plasmablast\|mild_COVID-19 / disease group, cell group and cell class (v2)	TYMS UCHL1 BUB1 PLK1 PKHD1L1	2.01e-05	186	79	5	a639d2183b85b1be6e6da2b2e112aec5149d5bcd
ToppCell	droplet-Spleen-SPLEEN-30m-Hematologic-nan\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TYMS MYH10 BUB1 ALDH1A1 PLK1	2.01e-05	186	79	5	7cdcf507a9a1349ed2cf62b79116367c3fc732dd
ToppCell	5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-Adventitial_fibroblasts_L.2.1.4.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CPXM2 ABI3BP UCHL1 CHRDL1 TNXB	2.01e-05	186	79	5	07d94d5d1c2fe7bb909a07ca81058a0eabc65c60
ToppCell	droplet-Pancreas-Exocrine-18m-Mesenchymal-pancreatic_stellate_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ABI3BP LRP2 CHRDL1 PKHD1L1 TNXB	2.07e-05	187	79	5	4e553721fa5598cb211f44e3226280b7e6885484
ToppCell	droplet-Pancreas-Exocrine-18m-Mesenchymal\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ABI3BP LRP2 CHRDL1 PKHD1L1 TNXB	2.07e-05	187	79	5	d36e7fc6125e7a4310499365022d38f34b757a73
ToppCell	droplet-Pancreas-Exocrine-18m-Mesenchymal-pancreatic_stellate_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ABI3BP LRP2 CHRDL1 PKHD1L1 TNXB	2.07e-05	187	79	5	827eae63fabf6892a82ce7779b5f395958d3d628
ToppCell	droplet-Spleen-SPLEEN-30m-Hematologic-megakaryocyte-erythroid_progenitor_cell\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TYMS MYH10 ALDH1A1 PLK1 PKHD1L1	2.07e-05	187	79	5	dceca7ae3dae96078cccc17a0d8a61b06fa6dffb
ToppCell	mild_COVID-19-Plasmablast\|World / disease group, cell group and cell class (v2)	TYMS UCHL1 BUB1 PLK1 PKHD1L1	2.12e-05	188	79	5	9a5ba6abdc307402301dae25db2a5f3e0d576417
Drug	Caffeine	TYMS TPRA1 USP11 UCHL1 NISCH BUB1 ALDH1A1 QARS1 PTGS2 RYR1 RYR2	1.83e-06	515	80	11	ctd:D002110
Drug	Moxisylyte hydrochoride [964-52-3]; Up 200; 12.6uM; MCF7; HT_HG-U133A	PASK TPRA1 ABI3BP INPP5B FBXO11 PRKAG2 RYR1	5.88e-06	196	80	7	7015_UP
Drug	Caffeic acid [3331-39-5]; Down 200; 22.2uM; MCF7; HT_HG-U133A	STK16 LMF1 THOP1 GANAB FARP1 INPP5B PRKAG2	6.28e-06	198	80	7	5352_DN
Drug	FPL 64176	CAPNS1 RYR1 RYR2	1.84e-05	15	80	3	CID000003423
Drug	iodoantipyrine	FATE1 AOC3 TNXB	2.74e-05	17	80	3	CID000008522
Drug	kazinol B	PTGS2 RYR1 RYR2	2.74e-05	17	80	3	CID000480869
Drug	methylcoumarin	CAPNS1 RYR1 RYR2	3.28e-05	18	80	3	CID000007092
Drug	cis-diammineplatinum(II	RYR1 RYR2	3.65e-05	3	80	2	CID000159790
Drug	2-hydroxyheptanoic acid	RYR1 RYR2	3.65e-05	3	80	2	CID002750949
Drug	8N3-cADPR	RYR1 RYR2	3.65e-05	3	80	2	CID000127713
Drug	aminodantrolene	RYR1 RYR2	3.65e-05	3	80	2	CID009570289
Drug	2-hydroxycarbazole	RYR1 RYR2	3.65e-05	3	80	2	CID000093551
Drug	Ryanodyl 3-(pyridine-3-carboxylate	RYR1 RYR2	3.65e-05	3	80	2	CID005748312
Drug	Mannans	MMP9 PTGS2	3.65e-05	3	80	2	ctd:D008351
Drug	resveratrol; Down 200; 10uM; MCF7; HT_HG-U133A_EA	NDST1 ARHGAP32 THOP1 PPP5C BUB1 PLK1	3.78e-05	177	80	6	841_DN
Drug	clioquinol	TYMS LRP1 LRP2 POLR1B PTGS2	5.14e-05	114	80	5	CID000002788
Drug	wortmannin; Down 200; 1uM; MCF7; HT_HG-U133A_EA	PASK LHX2 NDST1 THOP1 FBXO11 POLR1B	5.95e-05	192	80	6	977_DN
Drug	Methoxy-8-psoralen [298-81-7]; Up 200; 18.6uM; MCF7; HT_HG-U133A	STK16 NDST1 THOP1 BUB1 LRP2 ARHGAP33	6.31e-05	194	80	6	3302_UP
Drug	Phenelzine sulfate [156-51-4]; Down 200; 17uM; PC3; HT_HG-U133A	PASK NDST1 KCNB1 INPP5B LRP1 PTGS2	6.49e-05	195	80	6	3802_DN
Drug	radicicol, diheterospora chlamydosporia; Down 200; 0.1uM; MCF7; HT_HG-U133A	PASK LHX2 NDST1 THOP1 FAM114A2 PPP6R1	6.49e-05	195	80	6	6979_DN
Drug	Thioproperazine dimesylate [2347-80-0]; Down 200; 6.2uM; PC3; HT_HG-U133A	STK16 PASK LMF1 INPP5B WDFY3 RYR2	6.86e-05	197	80	6	5791_DN
Drug	estradiol, USP; Down 200; 0.1uM; MCF7; HT_HG-U133A	NDST1 ARHGAP32 TPRA1 LMF1 PPP5C POLR1B	7.06e-05	198	80	6	1633_DN
Drug	Lidoflazine [3416-26-0]; Down 200; 8.2uM; PC3; HT_HG-U133A	PASK LMF1 ABI3BP LRP2 FBXO11 RYR2	7.26e-05	199	80	6	5804_DN
Drug	PCB74	RYR1 RYR2	7.28e-05	4	80	2	CID000036218
Drug	2-aminoresorcinol	GANC AOC3	7.28e-05	4	80	2	CID000069450
Drug	148504-47-6	RYR1 RYR2	7.28e-05	4	80	2	CID006444275
Drug	SC 38249	RYR1 RYR2	7.28e-05	4	80	2	CID000134834
Drug	AC1L1U7A	RYR1 RYR2	7.28e-05	4	80	2	CID000035682
Drug	Flunixin meglumine [42461-84-7]; Down 200; 8.2uM; PC3; HT_HG-U133A	PASK BUB1 LRP1 DENND2D MMP9 ARHGAP33	7.46e-05	200	80	6	3713_DN
Disease	amino acid measurement	PASK ITGA11 MYH10 FARP1 NISCH CAPNS1 LRP2 MCCC1 RYR2 C16orf89	1.33e-05	678	79	10	EFO_0005134
Disease	congenital myopathy 1A (implicated_via_orthology)	RYR1 RYR2	2.12e-05	3	79	2	DOID:3529 (implicated_via_orthology)
Disease	malignant hyperthermia (implicated_via_orthology)	RYR1 RYR2	2.12e-05	3	79	2	DOID:8545 (implicated_via_orthology)
Disease	Chediak-Higashi syndrome (implicated_via_orthology)	WDFY3 WDFY4	4.23e-05	4	79	2	DOID:2935 (implicated_via_orthology)
Disease	Liver carcinoma	TYMS FATE1 PLXDC1 UCHL1 BUB1 MMP9 PLK1 PTGS2	6.44e-05	507	79	8	C2239176
Disease	polycystic liver disease (is_implicated_in)	GANAB ALG8	7.04e-05	5	79	2	DOID:0050770 (is_implicated_in)
Disease	Eye Diseases, Hereditary	LRP2 RPE65	1.05e-04	6	79	2	C0015398
Disease	Malignant neoplasm of pancreas	TYMS BUB1 MMP9 PTGS2	1.66e-04	102	79	4	C0346647
Disease	Diaphragmatic Hernia	KCNB1 UCHL1 LRP2	1.83e-04	41	79	3	C0019284
Disease	Bone neoplasms	MMP9 PTGS2	1.96e-04	8	79	2	C0005967
Disease	Malignant Bone Neoplasm	MMP9 PTGS2	1.96e-04	8	79	2	C0279530
Disease	Aortic Aneurysm, Abdominal	MMP9 PTGS2	3.14e-04	10	79	2	C0162871
Disease	Malignant neoplasm of tongue	TYMS PTGS2	3.14e-04	10	79	2	C0153349
Disease	Tongue Neoplasms	TYMS PTGS2	3.14e-04	10	79	2	C0040411
Disease	Premature Birth	MMP9 PTGS2	3.83e-04	11	79	2	C0151526
Disease	endometriosis (implicated_via_orthology)	HDAC3 PTGS2	3.83e-04	11	79	2	DOID:289 (implicated_via_orthology)
Disease	esophagus adenocarcinoma (is_marker_for)	MMP9 PTGS2	4.59e-04	12	79	2	DOID:4914 (is_marker_for)
Disease	congenital diaphragmatic hernia (implicated_via_orthology)	NDST1 LRP1	4.59e-04	12	79	2	DOID:3827 (implicated_via_orthology)
Disease	salicylurate measurement	LMF1 RYR2	5.42e-04	13	79	2	EFO_0010532
Disease	intracranial aneurysm (biomarker_via_orthology)	AOC3 MMP9	5.42e-04	13	79	2	DOID:10941 (biomarker_via_orthology)
Disease	Leber congenital amaurosis (implicated_via_orthology)	RDH11 DHRSX	5.42e-04	13	79	2	DOID:14791 (implicated_via_orthology)
Disease	Schizophrenia	HDAC3 ARHGAP32 KCNB1 LRP1 LRP2 ALDH1A1 MMP9 TNXB PTGS2	5.84e-04	883	79	9	C0036341
Disease	membranous glomerulonephritis (biomarker_via_orthology)	LRP2 MMP9	6.31e-04	14	79	2	DOID:10976 (biomarker_via_orthology)
Disease	Oral Submucous Fibrosis	MMP9 PTGS2	1.05e-03	18	79	2	C0029172
Disease	Gastric ulcer	MMP9 PTGS2	1.05e-03	18	79	2	C0038358
Disease	squamous cell carcinoma (is_marker_for)	MMP9 RPE65	1.18e-03	19	79	2	DOID:1749 (is_marker_for)
Disease	pulmonary hypertension (biomarker_via_orthology)	MMP9 RYR1 RYR2	1.31e-03	80	79	3	DOID:6432 (biomarker_via_orthology)
Disease	otitis media (implicated_via_orthology)	NISCH FBXO11	1.58e-03	22	79	2	DOID:10754 (implicated_via_orthology)
Disease	prostate carcinoma (is_marker_for)	HDAC3 PLK1	1.73e-03	23	79	2	DOID:10286 (is_marker_for)
Disease	Retinal Diseases	MMP9 RPE65	2.38e-03	27	79	2	C0035309
Disease	congestive heart failure (is_implicated_in)	NISCH RYR1	2.38e-03	27	79	2	DOID:6000 (is_implicated_in)
Disease	myocardial infarction (is_implicated_in)	LRP1 MMP9 PTGS2	2.41e-03	99	79	3	DOID:5844 (is_implicated_in)
Disease	sciatic neuropathy (biomarker_via_orthology)	LRP1 MMP9 QARS1	2.41e-03	99	79	3	DOID:11446 (biomarker_via_orthology)
Disease	Pancreatic Neoplasm	TYMS MMP9 PTGS2	2.48e-03	100	79	3	C0030297
Disease	pancreatic cancer (is_marker_for)	ALDH1A1 MMP9 PTGS2	2.55e-03	101	79	3	DOID:1793 (is_marker_for)
Disease	Hyperplasia	MMP9 PTGS2	2.56e-03	28	79	2	C0020507

Protein segments in the cluster

Peptide	Gene	Start	Entry
DELGIGTYHNIAFIH	PRKAG2	426	Q9UGJ0
NFYIFLVETGFHHVA	C16orf89	366	Q6UX73
DLHQFFEFLYNHGIG	BUB1	81	O43683
LVYVHHLLGEGAFAQ	BUB1	786	O43683
GHFDAVQYLLEHGAS	ANKRD60	231	Q9BZ19
NAVEFAHHGVFYHQG	ALDH1A1	286	P00352
SFHIEGAGALYNHLA	CCDC87	456	Q9NVE4
FEVYLVGNNSHHFII	CDH23	386	Q9H251
YNISGAGFFLHHVGL	AOC3	231	Q16853
EFHYIAGAHGNEVLG	CPXM2	371	Q8N436
QYFHVHGGIEFDIST	ANKAR	376	Q7Z5J8
QGYSLFLVAAHEFGH	MMP9	391	P14780
LFAHLHGYVSGEDVA	PASK	256	Q96RG2
HGGHSFIYLQEALQD	TRIM71	306	Q2Q1W2
AQGVLEHHTYGALLF	GPAA1	586	O43292
ELNHAFGLCHHGNYL	LRP1	741	Q07954
FHVHGENLFGAEYQL	ITGAE	991	P38570
IYVAGAFDLFHIGHV	PCYT2	216	Q99447
IAGLHFDQEVNHYKG	PCYT2	246	Q99447
HGVGHDYVQLAFKVF	PGM2L1	266	Q6PCE3
GELYLDDGHSFQYLH	GANC	811	Q8TET4
FILHGNRGVYHDDKQ	GXYLT1	361	Q4G148
GHAIHNDFKALQYFH	ISG20L2	261	Q9H9L3
EEIQFFNGHNYHKGI	NDST1	641	P52848
FTNGLGHGVDLNHIY	PTGS2	206	P35354
ALLQGEYPAHFNHAD	LHX2	171	P50458
QNRGVAVGVAFHYHL	LRP2	421	P98164
LEDNHAGAIYIFHGF	ITGA11	566	Q9UKX5
DFGGIFHTRYEQIHL	PRADC1	51	Q9BSG0
AHFHYENVEFGSIQL	ARHGAP32	121	A7KAX9
IHHGDGVQEAFYLTD	HDAC3	171	O15379
NSIGVFIFADHYGHQ	KBTBD8	151	Q8NFY9
FIFADHYGHQELGDR	KBTBD8	156	Q8NFY9
EFHLLGFGVQHEFQH	OR5AK3P	11	Q8NH89
GFGVQHEFQHVLFIV	OR5AK3P	16	Q8NH89
AYFHINVHDSGEGNI	PCDHB7	176	Q9Y5E2
HFHYENVDFGHIQLL	ARHGAP33	51	O14559
HTAIAFNFEAGVHQY	KCNB1	741	Q14721
TYQHGELFVAEGLFQ	CHRDL1	121	Q9BU40
NHLNLVEGDYFGLEF	FARP1	71	Q9Y4F1
EAHFDGLIFVHSGIY	FBXO11	281	Q86XK2
GAFEAAGFHLNEHLY	CAPNS1	196	P04632
RDGFEEHFGLNYLGH	DHRSX	141	Q8N5I4
EHFGLNYLGHFLLTN	DHRSX	146	Q8N5I4
HYGLLFDEFQGLSHL	FAM114A2	236	Q9NRY5
HLIYQFGGHHELIEY	AMDHD1	401	Q96NU7
VEVQVFGDHHGNAVY	MCCC1	256	Q96RQ3
FGDHHGNAVYLFERD	MCCC1	261	Q96RQ3
YRLEHGGQEHALFLY	INPP5B	41	P32019
SGHGDAHLQEYAGNF	FATE1	91	Q969F0
LLGHYNNFFFAAHLL	RYR1	4801	P21817
LGHYNNFFFAAHLLD	RYR2	4731	Q92736
FHIFYQLLSGAGEHL	MYH10	281	P35580
NFAGGQHFFEYLLVV	DENND2D	46	Q9H6A0
DYHLQNGDVVGQHSF	KIFAP3	741	Q92845
LHIGHAKAINFNFGY	QARS1	276	P47897
HFHNLQGEKFYNAGL	RDH11	186	Q8TC12
LFHHINTYEDNGFLI	RPE65	311	Q16518
FSYVDLVEGLHDGHF	STK16	31	O75716
FQVDHARSLHYVGAG	TMEM150A	131	Q86TG1
NLFGIFFILAAHEHY	SAMD8	331	Q96LT4
GDTHGQFYDLLNIFE	PPP5C	241	P53041
QGELFLDDGHTFNYQ	GANAB	841	Q14697
AFHGGNYRELYHILE	SIX6	61	O95475
LIVDHIHFQYNGFLF	ALG8	156	Q9BVK2
SEIFQGYHQRVHGAD	PRY	86	O14603
AHLSAEDFNIYGHGG	TPRA1	176	Q86W33
LPQNDLQHYAFHFEG	USPL1	426	Q5W0Q7
EAVNVFHHLFYEGQV	WDFY3	2926	Q8IZQ1
EGQFDHFLVQYRNGD	TNXB	2011	P22105
LAHFLHFHFYEINGI	NISCH	111	Q9Y2I1
HFHFYEINGITAALA	NISCH	116	Q9Y2I1
EGVLLFGHQHFYICE	WDFY4	2406	Q6ZS81
GDFIHTLGDAHIYLN	TYMS	246	P04818
FIGHHNVSFILDNDY	PKHD1L1	231	Q86WI1
SEFGNHYLYQIAHLG	SF3B3	351	Q15393
FHYVFNNFLHAQVEG	PPP6R1	391	Q9UPN7
FQAALHHDGRIVFAY	PLXDC1	221	Q8IUK5
AHVESFNYAVHEGLG	POLR1B	41	Q9H9Y6
KFYNIGDQRGHGEDH	ABI3BP	991	Q7Z7G0
GIYQELLGLAFHHEE	THOP1	371	P52888
VGHFASQFLGYQQHD	USP11	386	P51784
QQLADKYHFRGHLGD	XXYLT1	316	Q8NBI6
HFILFNNVDGHLYEL	UCHL1	161	P09936
QHVVGFHGFFEDNDF	PLK1	111	P53350
HFNSLHIVNTYGAFG	LMF1	396	Q96S06
NFHIFYQLLAGGEEE	MYO1H	201	Q8N1T3